Psoriasis is a chronic, immune-mediated inflammatory dermatosis that associates a number of conditions such as cardiovascular disease, metabolic syndrome, inflammatory bowel disease, neoplasia or psychiatric disorders, amongst the most frequent being depression and anxiety. This article aims to highlight the common pathogenetic pathway between psoriasis and psychiatric comorbidities, depression and anxiety, their prevalence among psoriasis patients, as well as the evolution of these conditions under psoriasis-specific systemic therapy (biological therapy and conventional systemic therapy) using specific scales to quantify depression severity and anxiety (HAM-D, HAM-A), determined at a certain time interval after the initiation of therapies. We conducted an observational study in the Dermatology Department of the Slatina Emergency County Hospital on a group of 51 patients clinically diagnosed with psoriasis. Thus, we found that the degree of mental impairment in the studied group was significant, 49% of patients showed mild depression, 15.7% moderate depressive episodes and 5.9% severe depression. Only 29.4% were not affected by depression. In terms of anxiety, 21.6% had moderate anxiety. Psoriasis is a chronic condition associated with the secretion of numerous pro-inflammatory cytokines. Increased levels of pro-inflammatory cytokines are also found in major depressive disorders. Thus, the common pathogenic pathway between psoriasis and depression may be the overexpression of proinflammatory cytokines such as IL-6, IL-17 or TNF-α. In the last two decades, with the advent of biological therapies, the treatment of psoriasis has evolved dramatically, and they have also had a positive impact on comorbidities, particularly psychiatric ones. RezumatPsoriazisul este o dermatoză inflamatorie cronică, imun-mediată, care asociază o serie de afecțiuni precum cele cardiovasculare, sindrom metabolic, boli inflamatorii intestinale, neoplazii sau tulburări psihiatrice, mai frecvent întâlnite fiind depresia și anxietatea. În acest articol ne propunem să evidențiem calea patogenică comună între psoriazis și comorbiditățile psihiatrice, depresie și anxietate, prevalența acestora în rândul pacienților cu psoriazis, dar și evoluția acestor afecțiuni sub terapie sistemică specifică pentru psoriazis (terapie biologică și terapie sistemică convențională) prin utilizarea unor scale specifice pentru cuantificarea gradului de depresie și anxietate (HAM-D, HAM-A), determinate la un anumit interval de timp de la inițierea terapiilor. Am efectuat un studiu observațional în cadrul Secției de Dermatologie a Spitalului Județean de Urgență Slatina, pe un lot format din 51 de pacienți diagnosticați clinic cu psoriazis. Astfel, am descoperit faptul că gradul de afectare psihică la lotul studiat a fost unul semnificativ, 49% dintre pacienți au prezentat depresie ușoară, 15,7% episoade depresive moderate, iar 5,9% depresie severă. Doar un procent de 29,4% nu era afectat de depresie. În ceea ce privește anxietatea, 21,6% prezentau anxietate moderată....
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.